Investment case
Illumina, Inc.
ILMN · 10 developments mapped · last assessed 2026-09-29
Market Ontology has mapped 10 macro, policy, and market developments to Illumina, Inc. since 2026-08-17. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for ILMN yet, so no modelled value is shown. The ILMN valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run ILMN on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Strongest support
Magnetic Bead Purification Market Forecast to Expand at 10.5% CAGR to $6.73B by 2030
Increased demand for sample preparation solutions, including magnetic beads, as a precursor to genomics sequencing workflows.
· Moves consumables revenue growth
- Open question
Pfizer and NVIDIA Commit $80M Joint Venture to AI Vaccine Adjuvant Discovery
While AI-driven drug discovery could increase demand for genomic sequencing (Illumina's core business), it also represents a shift towards computational methods that might reduce reliance on traditional lab workflows, potentially impacting some aspects of their business model or creating new competi
· Moves demand for genomic data, r&d investment in new technologies, competitive landscape
What changed, by assumption
- 2026-09-21Magnetic Bead Purification Market Forecast to Expand at 10.5% CAGR to $6.73B by 2030
- 2026-09-27Hangzhou Global Open-Source AI Challenge Awards 1M RMB to Peptide Algorithm
- 2026-09-27Hangzhou Global Open-Source AI Finals Conclude with 1M RMB Biotech Prize
- 2026-09-25Pfizer and NVIDIA Commit $80M Joint Venture to AI Vaccine Adjuvant Discovery
- 2026-08-17Illumina, Inc. Prices $300 Million 4.950% Notes due 2029
Assumption changes
Full ledger →| Date | Assumption | Direction | Why | Conf. |
|---|---|---|---|---|
| 2026-08-12 | Cost of capital | Bearish | IG cost of debt is below blended cost of capital; weighting effect lowers WACC. | 0.70 |
| 2026-08-12 | Interest expense | Bullish | New IG coupon adds to recurring interest expense. | 0.70 |
| 2026-08-12 | Net debt | Bullish | Investment-grade issuance adds gross debt to the balance sheet. | 0.70 |
| 2026-06-23 | Net debt | Bearish | Liability-management transactions often reduce gross debt or push maturities out. | 0.70 |
| 2026-06-23 | Interest expense | Bearish | Tender/exchange extends maturity profile and typically lowers near-term interest expense. | 0.70 |
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-29 | Quantum-Si Interim Proteus Data Shows 30x Alignment Gain Over Platinum Pro | watch | 3-12m | 0.30 |
| 2026-09-27 | Hangzhou Global Open-Source AI Challenge Awards 1M RMB to Peptide Algorithm | Bullish | 3-12m | 0.40 |
| 2026-09-27 | Hangzhou Global Open-Source AI Finals Conclude with 1M RMB Biotech Prize | Bullish | 1-3m | 0.40 |
| 2026-09-25 | Ginkgo Bioworks Inks $31M Contract with SaponiQx for AI Vaccine Adjuvants | Bullish | 3-12m | 0.20 |
| 2026-09-25 | Pfizer and NVIDIA Commit $80M Joint Venture to AI Vaccine Adjuvant Discovery | mixed | 1-5y | 0.40 |
| 2026-09-21 | Magnetic Bead Purification Market Forecast to Expand at 10.5% CAGR to $6.73B by 2030 | Bullish | 1-5y | 0.50 |
| 2026-09-20 | Twist Bioscience Surges 31% on Eli Lilly AI Drug Discovery Deal | watch | 3-12m | 0.20 |
| 2026-09-09 | FDA Approves Label Expansion for CRISPR Therapeutics Gene Therapy Casgevy | Bullish | 3-12m | 0.20 |
| 2026-08-31 | Tempus AI, Inc. to Acquire Personalis, Inc. in All-Stock Transaction | watch | 3-12m | 0.30 |
| 2026-08-17 | Illumina, Inc. Prices $300 Million 4.950% Notes due 2029 | mixed | 1-3m | 0.40 |